Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review

Radioligand therapy with Lutetium-177 (177Lu)-Prostate-specific membrane antigen (PSMA) has shown to prolong survival in metastatic castration resistant prostate cancer (mCRPC). One of the major challenges for clinicians in the future is to select those patients who would benefit most from this ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Heidegger, Isabel, Kesch, Claudia, Kretschmer, Alexander, Tsaur, Igor, Ceci, Francesco, Valerio, Massimo, Tilki, Derya, Marra, Giancarlo, Preisser, Felix, Fankhauser, Christian D., Zattoni, Fabio, Chiu, Peter, Puche-Sanz, Ignacio, Olivier, Jonathan, van den Bergh, Roderik C. N., Kasivisvanathan, Veeru, Pircher, Andreas, Virgolini, Irene, Gandaglia, Giorgio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902011/
https://www.ncbi.nlm.nih.gov/pubmed/35273651
http://dx.doi.org/10.1177/17588359221081922

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902011/
https://www.ncbi.nlm.nih.gov/pubmed/35273651
http://dx.doi.org/10.1177/17588359221081922

Ejemplares similares